Holmes has 20 years of experience in finance strategy and operations including roles as Chief Financial Officer of.

Catamaran bio funding. The leadership team at Catamaran Bio has deep expertise in cell therapy research and product development and the team includes. November 23 2020 Catamaran Bio a Cambridge Mass-based developer of developing allogeneic CAR-NK cell therapies to treat cancer raised 42 million in Series A fundingSofinnova Partners and Lightstone Ventures co-led and were joined by Takeda Ventures Astellas Venture Management and founding backer SV Health Investors. This deal was done in Cash.

Catamaran Bio is developing novel off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers including solid tumors. Catamaran Bio has 26 employees at their 1 location and 42 m in total funding. A biotechnology company Catamaran Bio Inc based in Cambridge has raised US 42 million financing in a Series A round on 23rd November 2020.

This round is a part of their launch financing. Announced Date Mar 30 2015. In addition funding will expand the companys TAILWIND Platform an integrated and proprietary suite of technologies for designing genetically engineering.

Celeste Richardson PhD Senior Vice President Research. Catamaran Bio Inc a Cambridge Mass. Catamaran Bio Inc a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer today announced that the company has launched with 42 million in financingSofinnova.

Catamaran Bio Inc in Cambridge Massachusetts is spun-off from medical school research labs at University of Minnesota and George Washington. Vipin Suri PhD MBA Chief Scientific Officer who has more than 20 years of biopharmaceutical experience including as a co-founder of Obsidian Therapeutics and Serien formerly Raze Therapeutics and earlier in R. April 26 2021 Catamaran Bio Inc a biotechnology company developing allogeneic CAR-NK cell therapies to treat patients with significant unmet medical need today announced the appointment of Scott Holmes MS MBA as Chief Financial OfficerMr.

Developer of allogeneic immune cell therapies intended to transform the treatment of cancer and immune disorders. The leadership team at Catamaran Bio has deep expertise in cell therapy research and product development and the team includes. It offers cell therapy company developing allogeneic off-the-shelf products for patients with an unmet medical need.